


# CD marker antibodies




Bulk Antibodies for *in vivo* Research

# CD marker antibodies

ANTIGEN	REACTIVITY	APPLICATION	CLONE	<i>InVivoMab</i> CATALOG	<i>InVivoPlus</i> CATALOG
CD1a	human	<i>in vitro</i> CD1a blockade, FC	OKT-6	BE0211	
CD1d	mouse	<i>in vivo</i> CD1d neutralization	19G11	BE0000	
CD1d	mouse	iNKT cell neutralization, <i>in vivo</i> CD1d blockade, FC	20H2 (HB-323)	BE0179	
CD3	human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> T cell depletion in humanized mice, <i>ex vivo</i> T cell inhibition for xenographs, FC	OKT-3	BE0001-2	
CD3	mouse	<i>in vitro</i> T cell stimulation/activation	17A2	BE0002	
CD3	human	<i>in vivo</i> T cell depletion in humanized mice, <i>ex vivo</i> T cell inhibition for xenographs, FC	UCHT1 (Leu-4)(T3)	BE0231	
CD3ε	mouse	<i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC	145-2C11	BE0001-1	BP0001-1
CD3ε	mouse	<i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF	KT3	BE0261	
CD3ε F(ab') <sub>2</sub> fragment	mouse	<i>in vivo</i> T cell depletion	145-2C11 f(ab') <sub>2</sub> Fragments	BE0001-1FAB	
CD4	mouse	<i>in vivo</i> CD4 <sup>+</sup> T cell depletion, FC	GK1.5	BE0003-1	BP0003-1
CD4	human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4 <sup>+</sup> T cell depletion in humanized mice, FC, IP	OKT-4	BE0003-2	
CD4	mouse	<i>in vivo</i> blockade of CD4 <sup>+</sup> T cell responses	YTS 177	BE0003-3	
CD4	mouse	<i>in vivo</i> CD4 <sup>+</sup> T cell depletion	YTS 191	BE0119	
CD4	human	<i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4 <sup>+</sup> T cell activation, IF, IHC-F, FC	RPA-T4	BE0288	
CD6	mouse		BX222	BE0163	
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, IF, FC	53-6.7	BE0004-1	BP0004-1
CD8α	human	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion in humanized mice	OKT-8	BE0004-2	
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion	2.43	BE0061	BP0061
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion	YTS 169.4	BE0117	BP0117
CD8β (Lyt 3.2)	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, <i>in vitro</i> CD8 blockade, IF	53-5.8	BE0223	
CD8	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, FC	116-13.1 (HB129)	BE0118	
CD11a (LFA-1α)	human	Functional assays, FC	R7-1	BE0192	
CD11a (LFA-1α)	human	<i>in vitro</i> LFA-1 neutralization	TS-1/22.1.1.13	BE0005	
CD11a (LFA-1α)	mouse	<i>in vivo</i> LFA-1 neutralization	FD441.8	BE0005-1	
CD11a (LFA-1α)	mouse	<i>in vivo</i> LFA-1 neutralization	M17/4	BE0006	
CD11b	mouse/human	<i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC	M1/70	BE0007	
CD18	mouse	<i>in vivo</i> LFA-1 neutralization	M18/2	BE0009	
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	
CD19	human	FC, Functional assays, IF	4G7	BE0281	
CD20	human/monkey	<i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	
CD22	mouse	FC, IP	Cy34.1	BE0011	
CD24	mouse	<i>in vitro</i> CD24 <sup>+</sup> cell depletion	J11d	BE0227	
CD25 (IL-2Rα)	mouse	<i>in vivo</i> regulatory T cell depletion, FC	PC-61.5.3	BE0012	BP0012
CD25 (IL-2Rα)	mouse	<i>in vivo</i> regulatory T cell inactivation	7D4	BE0013	
CD25 (IL-2Rα)	human	IP, IF	7G7B6	BE0014	
CD28	mouse	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade	37.51	BE0015-1	
CD28	mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	
CD28	rat	<i>in vitro</i> T cell stimulation/activation, FC	JJ319	BE0040	
CD28	human	<i>in vitro</i> T cell stimulation/activation	9.3	BE0248	
CD29	mouse	IF, FC	KMI6	BE0232	
CD32 (FcyRIIA)	human	<i>in vivo</i> FcyRIIA blockade in humanized mice, <i>in vitro</i> FcyRIIA blockade, ELISA, FC	IV.3	BE0224	
CD40	mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation, <i>in vitro</i> DC stimulation/activation	FGK4.5/FGK45	BE0016-2	BP0016-2
CD40	human	<i>in vitro</i> B cell stimulation, <i>in vitro</i> macrophage stimulation, Functional assays, FC	G28.5	BE0189	
CD44	mouse/human	<i>in vivo</i> CD44 neutralization	IM7	BE0039	
CD44	human	<i>in vitro</i> CD44 blockade, WB, IF	Hermes-1	BE0262	
CD45RB	mouse	<i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion	HB220	BE0019	
CD47	human	<i>in vitro</i> CD47 neutralization, <i>in vivo</i> CD47 neutralization in humanized mice, FC	B6H12	BE0019-1	
CD47 (IAP)	mouse	<i>in vivo</i> CD47 blockade, IF	MIAP301	BE0270	
CD47 (IAP)	mouse/human/rat	<i>in vivo</i> and <i>in vitro</i> CD47 blockade, IF	MIAP410	BE0283	
CD48	mouse	<i>in vivo</i> and <i>in vitro</i> CD48 blockade	HM48-1	BE0147	
CD49d (VLA-4)	mouse/human	<i>in vivo</i> and <i>in vitro</i> VLA-4 neutralization, FC	PS/2	BE0071	
CD54 (ICAM-1)	mouse	<i>in vivo</i> ICAM-1 neutralization	YN1/1.7.4	BE0020-1	
CD54 (ICAM-1)	human	<i>in vitro</i> T cell stimulation/activation, IF	R6-5-D6	BE0020-2	
CD62E (E-Selectin)	human	FC	CL2	BE0136	
CD62L	mouse	<i>in vivo</i> CD62L neutralization	Mel-14	BE0021	
CD70	mouse	<i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	
CD71	human	IHC-F, FC	OKT-9	BE0023	
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3/TIB-219	BE0175	
CD73	mouse	<i>in vivo</i> CD73 blockade	TY/23	BE0209	
CD80	rat	FC	3H5	BE0187	
CD80 (B7-1)	mouse	<i>in vivo</i> B7-1 blockade, Affinity chromatography	1G10	BE0134	



ANTIGEN	REACTIVITY	APPLICATION	CLONE	InVivoMab CATALOG	InVivoPlus CATALOG
CD80 (B7-1)	mouse	<i>in vivo</i> CD80 blockade, FC	16-10A1	BE0024	
CD86 (B7-2)	mouse	<i>in vivo</i> CD86 blockade, FC	GL-1	BE0025	
CD90 (Thy1)	mouse	<i>in vitro</i> T cell depletion	M5/49.4.1	BE0076	
CD90 (Thy1)	mouse	<i>in vivo</i> T cell depletion	T24/31	BE0212	
CD90.1 (Thy1.1)	mouse	<i>in vivo</i> T cell depletion	19E12	BE0214	
CD90.2 (Thy1.2)	mouse	<i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion	30H12	BE0066	BP0066
CD103	mouse	<i>in vivo</i> CD103 neutralization, IF, FC	M290	BE0026	
CD106 (VCAM-1)	mouse	<i>in vivo</i> VCAM-1 neutralization, IF	M/K-2.7	BE0027	
CD115 (CSF1R)	mouse	<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF-R1 neutralization, <i>in vivo</i> monocyte depletion, FC	AFS98	BE0213	
CD117 (c-Kit)	mouse	FC, IF, IHC	2B8	BE0280	
CD119 (IFN $\gamma$ R)	mouse	<i>in vivo</i> IFN $\gamma$ R neutralization	GR-20	BE0029	
CD119 (IFN $\gamma$ R)	human	Functional assays, IHC-F, WB, IP, FC	GIR-208	BE0286	
CD119 (IFN $\gamma$ R)	mouse	WB, IP, FC	2E2	BE0287	
CD120b (TNFR2)	mouse	<i>in vivo</i> and <i>in vitro</i> TNFR2 blockade	TR75-54.7	BE0247	
CD121a (IL-1 R)	mouse	<i>in vivo</i> IL-1 R blockade	JAMA-147	BE0256	
CD122 (IL-2R $\beta$ )	mouse	<i>in vitro</i> NK cell negative selection, IP, FC	5H4	BE0272	
CD127 (IL-7R $\alpha$ )	mouse	<i>in vivo</i> blocking of IL-7R $\alpha$ signaling, FC	A7R34	BE0065	
CD132 (common $\gamma$ chain)	mouse	<i>in vivo</i> $\gamma$ c blockade, Functional assays, IP, FC	3E12	BE0271	
CD134 (OX40)	mouse	<i>in vivo</i> and <i>in vitro</i> OX40 activation	OX-86	BE0031	
CD134L (OX40L)	mouse	<i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization	RM134L	BE0033-1	
CD137 (4-1BB)	mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BE0169	BP0169
CD137 (4-1BB)	mouse	<i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation	3H3	BE0239	
CD137L (4-1BBL)	mouse	<i>in vivo</i> 4-1BBL blockade	TKS-1	BE0110	
CD152 (CTLA-4)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC	UC10-4F10-11	BE0032	BP0032
CD152 (CTLA-4)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization	9H10	BE0131	BP0131
CD152 (CTLA-4)	mouse	<i>in vivo</i> CTLA-4 neutralization	9D9	BE0164	BP0164
CD152 (CTLA-4)	human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	
CD154 (CD40L)	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling	MR-1	BE0017-1	BP0017-1
CD161 (NK1.1)	mouse	<i>in vivo</i> NK cell depletion, FC	PK136	BE0036	BP0036
CD162 (PSGL-1)	mouse	<i>in vivo</i> PSGL-1 blockade, IHC-F	4RA10	BE0186	
CD183 (CXCR3)	mouse	<i>in vivo</i> CXCR3 neutralization, FC	CXCR3-173	BE0249	
CD209b (SIGN-R1)	mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	
CD210 (IL-10R)	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of IL-10/IL-10R signaling, FC	1B1.3A	BE0050	BP0050
CD223 (LAG-3)	mouse	<i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC	C9B7W	BE0174	BP0174
CD254 (RANKL)	mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	
CD262 (DR5)	mouse	<i>in vivo</i> and <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	
CD272 (BTLA)	mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	
CD272 (BTLA)	mouse	<i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	
CD272 (BTLA)	mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	
CD272 (BTLA)	mouse	FC	8F4	BE0210	
CD273 (PD-L2)	mouse	<i>in vivo</i> and <i>in vitro</i> PD-L2 blockade, IHC-F, FC	TY25	BE0112	
CD274 (PD-L1)	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC	10F.9G2	BE0101	BP0101
CD275 (ICOSL)	mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	
CD276 (B7-H3)	mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	
CD278 (ICOS)	mouse	<i>in vivo</i> blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	
CD278 (ICOS)	mouse	FC	27A12	BE0226	
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization	J43	BE0033-2	BP0033-2
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BE0146	BP0146
CD279 (PD-1)	human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	
CD279 (PD-1)	human	FC	J110	BE0193	
CD279 (PD-1)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC	29F.1A12	BE0273	BP0273
CD317 (BST2, PDCA-1)	mouse	<i>in vivo</i> pDC depletion	BX444	BE0255	
CD325 (N-cadherin)	human	WB, IF, FC	8C11	BE0184	
CD340 (HER2/neu)	human/rat	<i>in vivo</i> and <i>in vitro</i> HER2 inhibition, IP, IF, FC	7.16.4	BE0277	
CD365 (TIM-1)	mouse	<i>in vivo</i> TIM-1 neutralization	RMT1-10	BE0113	
CD365 (TIM-1)	mouse	<i>in vivo</i> TIM-1 activation, <i>in vitro</i> T cell stimulation/activation, Functional assays, ELISA, FC	3B3	BE0289	
CD366 (TIM-3)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BE0115	BP0115
CD366 (TIM-3)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	B8.2C12	BE0275	



1-866-787-3444 | [bxcell.com](http://bxcell.com) | [customerservice@bxcell.com](mailto:customerservice@bxcell.com)

© Bio X Cell 2017